{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"134.12","value":"299.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Zanubrutinib 160 mg twice a day orally with or without food; Obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2 to 6; and then every 8 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; each cycle is 28 days","id":"OG000","title":"Zanubrutinib + Obinutuzumab"}],"paramType":"MEAN","populationDescription":"The Pharmacokinetics (PK) Analysis Set included all zanubrutinib-treated participants who had at least one post-baseline PK concentration measurement.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (2 hours postdose) and Cycle 2 Day 1 (predose and 2 hours postdose)","title":"Maximum Observed Concentration (Cmax) of Zanubrutinib at Steady State","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/ml)"}